Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
72%
Europe
40%
Antiretroviral Therapy
33%
Luxembourg
25%
Protease
18%
AIDS/HIV
16%
People Who Inject Drugs
16%
Hepatitis C Virus
15%
HIV-1 Infection
14%
C-X-C Chemokine Receptor Type 4 (CXCR4)
14%
Protease Inhibitors
14%
Infectious Diseases
14%
Viral Load
13%
European Union
13%
HIV-infected Patients
13%
Natural Killer Cells
12%
C-C Chemokine Receptor Type 5 (CCR5)
12%
Virus
12%
Rwanda
11%
Resistance mutations
11%
Highly Active Antiretroviral Therapy (HAART)
11%
Resistance Evaluation
10%
Hepatitis B Virus
10%
Virological Failure
10%
HIV Epidemic
10%
Hepatitis C Virus Infection
10%
HIV Infection
9%
Lamivudine
9%
Ritonavir
9%
Polymorphism
9%
Viral
8%
Genetic Resistance
8%
Direct-acting Antivirals
8%
European Economic Area
8%
Transmitted Drug Resistance
8%
Reverse Transcriptase
8%
Drug Resistance mutations
7%
Molecular Epidemiology
7%
Recombinant
7%
Integrase Strand Transfer Inhibitor (INSTI)
7%
Drug Resistance
7%
Plasma Viral Load
7%
People Living with HIV (PLHIV)
7%
Disease Burden
7%
Drug-likeness
7%
N-terminus
7%
Hepatitis B
6%
EMCDDA
6%
Circulating Recombinant Form
6%
Public Health Risk
6%
HIV Transmission
6%
Multimeric
6%
Global Prevalence
6%
Europe-Asia
6%
Central Asia
6%
European Countries
6%
Global Survey
6%
Non-B Subtypes
6%
HIV-infected children
6%
Chemokine Receptor
6%
COVID-19
6%
Africa
6%
Functional Components
6%
Disease Prevention
6%
HIV Drug Resistance
6%
Immunotherapeutics
6%
AIDS Surveillance
6%
Complementarity-determining Region 3 (CDR3)
6%
Human Immunodeficiency Virus Type 1 Protease
6%
Protein Complex
6%
Late Presentation
6%
HIV Drug Resistance Testing
6%
Pre-Omicron
6%
Breakthrough Infection
6%
Heavy Chain
6%
Bulgaria
6%
Zidovudine
6%
Hepatitis C
6%
Efavirenz
5%
Peripheral Blood Mononuclear Cells
5%
Naïve Patients
5%
CRF01_AE
5%
Resistance-associated Substitutions
5%
Antiviral Drugs
5%
WHO European Region
5%
Elimination Goals
5%
Total HIV DNA
5%
Living with
5%
CD8+ T Cells
5%
Treatment-naïve
5%
Chemokines
5%
Humanized Mice
5%
Sub-epidemic
5%
Cassia Abbreviata
5%
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Infection
50%
Infectious Disease
47%
Human Immunodeficiency Virus
40%
Prevalence
25%
Drug Resistance
24%
Viral Load
21%
Protease
20%
Proteinase
20%
Virus
20%
Peptides
13%
Blood Plasma
13%
In Vitro
13%
Natural Killer Cell
12%
CXCR4
11%
Hepatitis C Virus
10%
Hepatitis B Virus
10%
Reverse Transcriptase
8%
Cytotoxic T-Cell
8%
Hepatitis B
8%
Molecular Epidemiology
7%
Integrase
7%
Amino Terminal Sequence
7%
CCR5
6%
Omicron Coronavirus Variant
6%
Peripheral Blood Mononuclear Cell
6%
Breakthrough Infection
6%
Heavy Chain
6%
Ribonucleic Acid
6%
Factor H
6%
Replication
5%
Bacteriophage
5%
Chemokine
5%
T-Helper Cell
5%
CD4
5%
Neutralization
5%
Cross-Resistance
5%